Ankebin;Antara;Elasterate;Elasterin;Fenobrate;Fenogal;Fenotard;Lipanthyl;Lipantil;Lipidex;Lipidil;Lipidil Micro;Lipidil Supra;Lipifen;Lipirex;Lipoclar;Lipofene;Liposit;Lipsin;Lofibra;Luxacor;Nolipax;Procetofen;Proctofene;Protolipan;Secalip;Sedufen;Tricor;Triglide;Trilipix (Abbott Laboratories);

Fenofibrato [INN-Spanish];Fenofibratum [INN-Latin];Fenofibric acid;Finofibrate;FNF;

An antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]

• Abbott laboratories
• Abbott laboratories pharmaceutical products div
• Ar holding co inc
• Cipher pharmaceuticals inc
• Impax laboratories inc
• Lupin atlantis holdings sa
• Mylan pharmaceuticals inc
• Ranbaxy laboratories ltd
• Shionogi pharma inc
• Skyepharma ag
• Teva pharmaceuticals usa inc

Synthesis Reference

Not Available

General Reference

Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7. Pubmed Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61. Pubmed

Form	Route	Strength
Capsule	Oral
Tablet	Oral

Unit description	Cost	Unit
Triglide 160 mg tablet	6.39 USD	tablet
Fenoglide 120 mg tablet	5.17 USD	tablet
Antara 130 mg capsule	5.13 USD	capsule
Tricor 145 mg tablet	4.69 USD	tablet
Lipofen 150 mg capsule	3.55 USD	capsule
Lofibra 200 mg capsule	3.25 USD	capsule
Lofibra 160 mg tablet	3.11 USD	tablet
Fenofibrate Micronized 200 mg capsule	2.77 USD	capsule
Fenofibrate 160 mg	2.47 USD	tablet
Fenofibrate 160 mg tablet	2.38 USD	tablet
Lofibra 134 mg capsule	2.03 USD	capsule
Antara 43 mg capsule	1.8 USD	capsule
Fenofibrate Micronized 134 mg capsule	1.79 USD	capsule
Fenoglide 40 mg tablet	1.72 USD	tablet
Tricor 48 mg tablet	1.63 USD	tablet
Triglide 50 mg tablet	1.49 USD	tablet
Lipidil Supra 160 mg Tablet	1.4 USD	tablet
Lofibra 67 mg capsule	1.26 USD	capsule
Lipidil Micro 200 mg Capsule	1.23 USD	capsule
Lipidil Supra 100 mg Tablet	1.22 USD	tablet
Apo-Feno-Micro 200 mg Capsule	1.14 USD	capsule
Fenofibrate Micro 200 mg Capsule	1.14 USD	capsule
Mylan-Fenofibrate Micro 200 mg Capsule	1.14 USD	capsule
Novo-Fenofibrate Micronized 200 mg Capsule	1.14 USD	capsule
Pms-Fenofibrate Micro 200 mg Capsule	1.14 USD	capsule
Ratio-Fenofibrate Mc 200 mg Capsule	1.14 USD	capsule
Fenofibrate Micronized 67 mg capsule	1.0 USD	capsule
Lofibra 54 mg tablet	0.99 USD	tablet
Fenofibrate 54 mg tablet	0.81 USD	tablet
Apo-Feno-Super 160 mg Tablet	0.79 USD	tablet
Novo-Fenofibrate-S 160 mg Tablet	0.79 USD	tablet
Sandoz Fenofibrate S 160 mg Tablet	0.79 USD	tablet
Apo-Feno-Super 100 mg Tablet	0.68 USD	tablet
Novo-Fenofibrate-S 100 mg Tablet	0.68 USD	tablet
Sandoz Fenofibrate S 100 mg Tablet	0.68 USD	tablet
Apo-Fenofibrate 100 mg Capsule	0.64 USD	capsule
Apo-Feno-Micro 67 mg Capsule	0.45 USD	capsule
Novo-Fenofibrate Micronized 67 mg Capsule	0.45 USD	capsule

Type	small molecule

Classes

Benzophenones

Substructures

Carboxylic Acids and Derivatives Acetates Phenols and Derivatives Phenoxyacetates Short-chain Hydroxy Acids Ethers Benzene and Derivatives Aryl Halides Halobenzenes Aromatic compounds Anisoles Benzophenones Benzoyl Derivatives Phenyl Esters Ketones

hyperlipidemi 高血脂;

Indication	For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Pharmacodynamics	Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.
Mechanism of action	Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
Absorption	Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Volume of distribution	95 L [moderate renal impairment (creatinine clearance of 50 to 90 mL/min)] 30 L [healthy adults]
Protein binding	~99% (Serum protein binding)
Metabolism
Route of elimination	Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.
Half life	20 hours
Clearance	1.2 L/h [Eldery]
Toxicity	LD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.
Affected organisms	Humans and other mammals
Pathways	Not Available

Properties
State	solid
Melting point	80.5 oC
Experimental Properties	Property Value Source water solubility 0.25mg/ml at 25 oC PhysProp logP 5.3 PhysProp
Predicted Properties	Property Value Source water solubility 7.07e-04 g/l ALOGPS logP 4.86 ALOGPS logP 5.28 ChemAxon Molconvert logS -5.71 ALOGPS pKa ChemAxon Molconvert hydrogen acceptor count 3 ChemAxon Molconvert hydrogen donor count 0 ChemAxon Molconvert polar surface area 52.60 ChemAxon Molconvert rotatable bond count 7 ChemAxon Molconvert refractivity 97.13 ChemAxon Molconvert polarizability 38.15 ChemAxon Molconvert

Drug	Interaction
Acenocoumarol	Fenofibrate may increase the anticoagulant effect of acenocoumarol.
Anisindione	Fenofibrate may increase the anticoagulant effect of anisindione.
Atorvastatin	Increased risk of myopathy/rhabdomyolysis
Cerivastatin	Increased risk of myopathy/rhabdomyolysis
Dicumarol	Fenofibrate may increase the anticoagulant effect of dicumarol.
Fluvastatin	Increased risk of myopathy/rhabdomyolysis
Lovastatin	Increased risk of myopathy/rhabdomyolysis
Pravastatin	Increased risk of myopathy/rhabdomyolysis
Rosuvastatin	May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy.
Simvastatin	Increased risk of myopathy/rhabdomyolysis
Ursodeoxycholic acid	The fibric acid derivative decreases the effect of ursodiol
Warfarin	Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed.

• Increased absorption- take with meals.